Silo Pharma merges traditional therapeutics with psychedelic research to develop innovative solutions that address a variety of underserved conditions including Alzheimer’s, Fibromyalgia, Parkinson’s, Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), as well as stress-induced psychiatric disorders (i.e. PTSD) and other debilitating chronic conditions. We talk about the research and the conditions you choose to study in conjunction with psychedelic treatment.
Silo has partnered with several leading academic institutions (the University of California, San Francisco, Columbia University, and the University of Maryland, Baltimore) to facilitate a streamlined regulatory pathway for drug approval. The company has developed a pipeline of proprietary licensed therapeutics that show promise for a range of illnesses and diseases.
Silo Pharma Inc. has begun dosing in its IND-enabling study of a proprietary time-released, topical formulation of ketamine SP-26 designed to treat fibromyalgia. The safety evaluation trial will be conducted by Experimur, a Frontage Company, and intends to evaluate the tolerability of SP-26 to establish a maximum dose in the treatment of this chronic medical condition causing widespread musculoskeletal pain as well as memory issues, sleep difficulties, and fatigue.